Abstract
Scedosporiosis in Thailand is mostly caused by Scedosporium boydii, which is known to be resisted to anti-fungal drugs resulting in death from infection. Most of the organs that shown disease pathology are cerebral edema and pulmonary disorders. Currently, there are many substances that can enhance the performance of antifungal drugs. It was found that substances that have been studied and developed for use in the treatment of many types of fungal infections are substances in the group of fungal Quorum sensing molecules. In laboratory studies, the Farnesol group at 100 µM can inhibit Scedosporium boydii infection without any toxicity effect to target cells. When confirmed the results of experiments in neutropenia-induced mice with Cyclophosphamide, it was found that the pathogenesis of the brain can be reduced clearly. The results of studies in mice that were inserted in the Catheter coated with Farnesol (F +) compared with those that were not coated with Farnesol (F-) shown that the amount of Scedosporium boydii at the hollow tube of the Catheter was lesser in F + group than F- group by Scanning Electron Microscopy. Moreover, the treated catheter was further cultured, which shown the lesser amount of infection or the formation of colony in F+ group than F- group (p <0.05). When comparing pathological examination between groups that were inserted Catheter, it was found that the F-group had symptoms of disseminated Scedosporiosis clearer than the F + group. It was found that the rats from F- group exhibited brain edema with severe damaged of alveolar septum and pulmonary edema. Based on the above study, both laboratory studies and animal studies as well as the underlying medical prototype product, the Catheter revealed that quorum sensing molecules, Farnesol, played an important role in inhibiting the growth of Scedosporium boydii. This preliminary study will help to develop a research in depth into the development of effective medical product. Moreover, study of other types of Scedosporium spp. should be further extended as well as the larger sample size of animal experiments. The interaction between Farnesol and the existing antifungal drugs including the study of pharmacokinetics in both in vitro and in vivo models need to be further elucidated.
